Education
About Us
Working with TipRanks
Follow Us
Outset Medical (OM)
NASDAQ:OM
Earnings Data
Report Date
May 06, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.74Last Year’s EPS
-3.24Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call highlighted clear operational and financial progress: revenue growth, material gross margin expansion, reduced operating expenses and cash burn, a strengthened balance sheet, strong customer satisfaction, and strategic momentum from FDA clearance of a cyber-hardened next-generation Tablo. Lowlights include lingering net losses, continued cash use (though improved), manufacturing under-absorption headwinds, product revenue timing variability, and long enterprise sales cycles. On balance, the positives around margin expansion, cost discipline, product leadership (cyber clearance), and improved cash runway outweigh the remaining challenges.Company Guidance
Full-Year Revenue Growth
Fiscal 2025 revenue of $119.5M, up 5% versus 2024, with management expecting 2026 revenue of $125M–$130M (a 5%–9% increase).
Quarterly and Product Details
Q4 revenue of $28.9M included $19.9M product revenue (console sales +11% to $6.4M) and $13.5M consumables; consumables rebounded sequentially, growing ~11% over Q3.
Significant Gross Margin Expansion
Non-GAAP gross margin expanded ~500 basis points YoY to 42.9% in Q4 and full-year non-GAAP gross margin rose 400 bps to 39.6% (41.1% excluding manufacturing under-absorption). Product gross margin reached 50.7% (+640 bps YoY) — the first time product margin exceeded 50%.
Improved Profitability Trajectory and Expense Discipline
Non-GAAP operating expenses declined ~4% in Q4 to $25.7M and full-year non-GAAP operating expenses fell 19% to $97.8M. Non-GAAP net loss narrowed to $65.4M for the year (31% improvement YoY) and Q4 non-GAAP net loss fell 22% YoY to $15M.
Stronger Cash Position and Reduced Cash Burn
Ended Q4 with $173M in cash, cash equivalents and investments, used ~$9M in the quarter and reduced full-year cash use to $46M in 2025 (down from $116M in 2024). Management expects 2026 cash use to be lower than $46M and believes cash on hand is sufficient to reach profitability.
FDA Clearance and Product Leadership
Received FDA clearance for next-generation Tablo (first dialysis system cleared under FDA's 2025 cybersecurity requirements). Launch planned late Q2; upgrade available to installed base. Tablo now used at ~1,000 acute care sites and consoles have delivered over 3M cumulative treatments.
Clinical & Customer Momentum
Expanded published evidence of improved clinical outcomes (lower infection rates, reduced length of stay), maintained CSAT >95%, and continued to expand master sales and service agreements including a deal covering 100+ facilities.
OM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
OM Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 11, 2026 | $4.54 | $3.80 | -16.30% |
Nov 10, 2025 | $12.07 | $6.22 | -48.47% |
Aug 06, 2025 | $13.17 | $14.18 | +7.67% |
May 07, 2025 | $11.74 | $15.88 | +35.26% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Outset Medical (OM) report earnings?
Outset Medical (OM) is schdueled to report earning on May 06, 2026, After Close (Confirmed).
What is Outset Medical (OM) earnings time?
Outset Medical (OM) earnings time is at May 06, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is OM EPS forecast?
OM EPS forecast for the fiscal quarter 2026 (Q1) is -0.74.